Merck ' s Keytruda Wins FDA Approval as Combination Therapy for Kidney Cancer Merck ' s Keytruda Wins FDA Approval as Combination Therapy for Kidney Cancer
The U.S. Food and Drug Administration has approved Merck& Co Inc ' s cancer therapy Keytruda (pembrolizumab) as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Hematology | Kidney Cancer | Merck | Urology & Nephrology